Share Name Share Symbol Market Type Share ISIN Share Description
Shield Therapeutics Plc LSE:STX London Ordinary Share GB00BYV81293 ORD 1.5P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 83.50 3,184 08:00:11
Bid Price Offer Price High Price Low Price Open Price
82.00 85.00 83.50 82.50 82.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 11.88 -5.15 -2.00 98
Last Trade Time Trade Type Trade Size Trade Price Currency
09:18:09 O 2,317 83.11 GBX

Shield Therapeutics (STX) Latest News

More Shield Therapeutics News
Shield Therapeutics Takeover Rumours

Shield Therapeutics (STX) Discussions and Chat

Shield Therapeutics Forums and Chat

Date Time Title Posts
08/4/202011:22Shield Therapeutics 2,862
22/2/202021:14Seagate Technology2,674

Add a New Thread

Shield Therapeutics (STX) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2020-04-08 14:56:3084.852,5002,121.25O
2020-04-08 14:32:3785.005,0004,250.00O
2020-04-08 14:21:2684.8510387.40O
View all Shield Therapeutics trades in real-time

Shield Therapeutics (STX) Top Chat Posts

Shield Therapeutics Daily Update: Shield Therapeutics Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker STX. The last closing price for Shield Therapeutics was 83.50p.
Shield Therapeutics Plc has a 4 week average price of 40p and a 12 week average price of 40p.
The 1 year high share price is 201p while the 1 year low share price is currently 40p.
There are currently 117,088,657 shares in issue and the average daily traded volume is 55,353 shares. The market capitalisation of Shield Therapeutics Plc is £97,769,028.60.
crankyman: I suppose all this was just co-incidence - The H2H release and the share dump due to the CV19 crash combined to trash the share price. How much the H2H issue contributed to it is proportional to how ignorant the market is of the the true importance of the issue - which was always minute. That ignorance is a money making opportunity. I didn't risk more by buying in at 50p because the CV19 crash will initiate a depression and that could undermine the viability of this company. I'm still in but to add, you have to be able to be confident that CV19 will pass without killing a deal short term. I still think it won't but it would not have helped.
crankyman: By the way, this data was not in the US label so a US partner could not use it in med comma anyway. Does this justify a 75% fall in the share price?
crankyman: Only question I have is whether they would announce a deal with this crash going on. My feeling is that they would as it's not going to make a difference medium/long term. The share price will find its level and a bit of good news wouldn't hurt to de-risk it further.
marie1980: Please share here Nobby.. Trust me I’m really frustrated with this share price. I’ve recommended this to so many people and they kept asking me. I don’t understand why share price is going down.
bioking: DNL is like buying STX last year at 40p before FDA approval -DNL likely to get approval for 2 Big Drugs in USA and Europe later this year The most underpriced and attractive british biotech company with MASSIVE upside potential .Still think this sleeping giant has 10+ bagger upside potential and 2020 could be the year for DNL with all the approvals and partnerships expected during the year .GL Diurnal (DNL) Market Cap £24 M Price: 28p DCF valuation of 202p per share Investment summary:Alkindi, a cortisol replacement therapy designed for children under 18 years of age, is DNL’s first product on the market. It is expected to be followed by Chronocort for adults – a larger market – which now has a clear pathway for regulatory approval in both Europe and the US. Despite this, the share price is still languishing well below valuations determined by peer group and DCF (202p) analyses Presentation hxxps:// Upcoming Catalysts: US-NDA acceptance for Alkindi in Februry 2020 MAA-Acceptance for Chronocort in February/March 2020 Alkindi approval in Israel expected in 1Q 2020 Alkindi approval in Australien expected in 2Q 2020 US-Partnership for Alkindi & Chronocort expected in 1H 2020 Alkindi & Chronocort Partnership for Asia für Japan und China US-Approval for Alkindi expected in 4Q 2020 EU Approval for Chronocort expected in 4Q/1Q 2020/21 $88m market opportunity (Europe and US) for Paediatric AI (inc CAH) $351m market opportunity (Europe and US) for Congenital Adrenal Hyperplasia $2,767m market opportunity (Europe and US) for Adrenal Insufficiency Ceo bought another 25k shares at 30p hxxps://
borromini1: 250 GBX would be very nice. Otherwise difficult to calculate when still early days for revenue. As Edison stated on 26 July 2019 ... Successfully commercialising Feraccru/Accrufer through partners is now key to Shield realising its value ... We now value Shield at 273m. Current market capitalisation = 210 million GBP Number of shares = 117 million Current share price = 180 GBX After deal share price, say 250 GBX After deal market capitalisation = 292 million GBP Patent expiry 2034 Years for revenue growth towards substantial earnings per share, say 4 years Subsequent investment pay back period, say 10 years On the above basis to return original investment capital, someone buying in at 250 GBX might be assuming ... Earnings total per year average over 10 year pay back period = 29.2 million GBP Earnings per share per year average over 10 year pay back period = 25 GBX To make any profit they need to see more than these figures or sell to the next believer. Ferinject in market sales for 2018 = 900 million USD = 693 million GBP Vifor Pharma Ferinject global sales revenue for 2018 = 380 million GBP Vifor revenue to market sales ratio = 55 percent Edison Feraccru/Accrufer peak in market sales figures USA = 420 million USD = 323 million GBP Norgine EU 5 = 130 million Euros = 110 million GBP Total in market sales = 433 million GBP Shield revenue to market sales ratio say same as Vifor at 55 percent Shield peak revenue = 238 million GBP Comments, additions and corrections welcome
secret investor: On 78steve's suggestion that a US deal is already priced-in, it's worth pointing out that the share price peaked at 188p in early April 2016 (shortly after the IPO). In the intervening 3.5 years then we've had EMA approval, the Norgine deal, growing sales and revenues, and FDA approval - and the share price is currently only 188p (the same as in April 2016)!
kop202: Its typical AIM. The share price is "made up" by the intermediaryIn the development phase they inflate the share price based on what the company could be potentially. Punters get carried away......Then before the potential is likely to be realised they drop the share price and base it on fundamentals......and leave there...AIM is run by City Scum.
crankyman: 50 million adds a half again to the share price. That's 270p. A big pharma player allocating 100 million to selling the product over 3-5 years is like Shield getting another 40 million it doesn't need to spend to get the US revenue stream. I still think the market doesn't believe in this product. THe share price would not be where it is if anyone thought this is truly going to sell anywhere near its potential in the US.
stevee1234: Hi Nobby, yes agree more buys recently, maybe we're about as low as it gets before more buyers stop the drop. I'm just trying to explain why I believe the share price has moved as it has over the last three weeks. It's a question of "do sellers prompt the share price to drop" or "do price drops prompt holders to sell" obviously a bit of both but on AIM I think the MMs know that when a share has had a good run recently dropping the price can often stimulate profit taking and hence allow them to get some shares back ready for the next upward step. I believe people are more motivated to buy when the chare price rises and sell when the share price falls, hence when stx stalled at 120ish they have been progressively stimulating the market by dropping the price, hopefully in coming weeks they'll be stimulating the market by raising the price. Still as I said everything crossed for the main event hopefully soon.
Shield Therapeutics share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Shield The..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200409 08:36:38